This course is not available at this time
Return to Course LibraryPrint Course MaterialsBibliographyGlossary

Release Date:
June 2011

Expiration Date:
June 30, 2013




FACULTY




Peter Caravan, PhD
Assistant Professor of Radiology
Massachusetts General Hospital
Harvard Medical School



A. Gregory Sorensen, MD
Professor of Radiology and Health Sciences & Technology
Co-Director of the A. A. Martinos Center for Biomedical Imaging
Massachusetts General Hospital
Harvard Medical School




Minimum Equipment Requirements

PC: Windows XP/Vista/Windows7, Pentium processor or faster, at least 512 MB RAM, Internet Explorer version 8, Mozilla FireFox version 3.

MAC: OS version 10.4./10.5/10.6, G4 processor or faster, at least 512 MB RAM.

Safari version 5, FireFox version 3.





 

Format: Online Self-study
Credit:  1.0 AMA PRA Category 1
Credit:  1.0 ACPE CEU
Credit:  1.0 ARRT Category A+
Fee for Credit Certificate: $0

Click the ENROLL NOW icon to the left to view this program ONLINE.




MRI Contrast Agents
Emerging Issues in Safety and Efficacy


A one-hour certified online activity for radiologists, health system pharmacists, hospital administrators and advanced-level radiologic technologists.

 

Course Overview

Given the current literature and emerging information about the link between the structural class of MRI gadolinium-based contrast agents (GBCAs) and adverse events, radiologists, health system pharmacists, and radiology administrators need to recognize the differences in the physical and chemical properties of MRI GBCAs and how these properties link to the incidence of adverse events and the safety of those patients receiving MR imaging.

 

Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Categorize MRI gadolinium-based contrast agents (GBCAs) into one of the following structural classes: nonionic linear, ionic linear, and macrocyclic
  • Describe how the structural class of a GBCA relates to the complex stability of an agent
  • Recognize the relationship between complex stability and the potential impact on patient safety
  • Provide accurate and appropriate counsel as part of the treatment team

Accreditation & Credit

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the International Center for Postgraduate Medical Education (ICPME). PIM is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Pharmacist Continuing Education

Accreditation Statement



Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for a maximum of 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - 809-9999-11-060-H05-P)

Type of Activity
Knowledge

 

Radiologic Technologists

This program has been approved by the American Society of Radiologic Technologists (ASRT) for 1.0 hour of ARRT Category A+ continuing education credit.


How to Participate in this Activity

  • Log in to your account at www.icpme.us.
  • Click ENROLL NOW and follow the instructions to enroll in this activity.
  • The activity will be accessible from your MY ACCOUNT page.


How to Apply for Credit

  • There are no fees to apply for credit.
  • Estimated time to complete this activity is 60 minutes.
  • To receive credit, view the entire program and submit the required POSTTEST and EVALUATION.

      How to submit the POSTTEST and EVALUATION

  • Go to www.icpme.us
  • Log-in to your account by clicking LOG IN in the upper right corner of the home page
  • Click MY ACCOUNT in the upper right corner of your computer screen
  • To access the course click on the course name located in your online account 


Faculty Biographies

Peter Caravan, PhD
Assistant Professor of Radiology
Massachusetts General Hospital
Harvard Medical School


Dr. Caravan received his BSc (Honors) at Acadia University and his PhD in chemistry from the University of British Columbia, followed by an NSERC postdoctoral fellowship at the Université de Lausanne. He then spent nine years at Epix Pharmaceuticals, developing tissue-specific and responsive MRI contrast agents where he was ultimately responsible for all chemistry and contrast agent research at the company. He is co-inventor of EP-2104R, a fibrin-specific contrast agent for thrombus detection that is the first molecular MR imaging agent to enter into human clinical trials. He joined the radiology faculty at Harvard Medical School and Massachusetts General Hospital in 2007. Dr. Caravan’s current research focus is on the development and application of new PET and MR imaging probes and exploiting the inherent synergies in dual PET-MR imaging.
 
Dr. Caravan has contributed seven book chapters and nine review articles on the chemistry, properties, and uses of imaging agents over the last 10 years. He has published over 50 peer reviewed papers on synthetic organic, inorganic, and physical chemistry of imaging probes, the biophysics of the interactions of these probes with proteins, and their application in animal models of disease. Dr. Caravan is co-inventor on 15 granted or pending patents related to new imaging agents and methods for their use.



A. Gregory Sorensen, MD
Professor of Radiology and Health Sciences & Technology
Co-Director of the A. A. Martinos Center for Biomedical Imaging
Massachusetts General Hospital
Harvard Medical School


Dr. Sorensen received his medical degree from Harvard Medical School and completed his residency and fellowship training at Massachusetts General Hospital.

Dr. Sorensen's research focus has been on bringing novel technical developments in functional magnetic resonance imaging to the investigation of neurologic disease and the care of patients. Additionally, he has worked to bring radiology tools to clinical research, particularly in the evaluation of novel interventions. In the clinical trials arena, this work has been in concert with industrial sponsors who wish to use radiologic techniques to rapidly evaluate new therapies. Dr. Sorensen’s techniques have been employed by 56 centers throughout the world in Phase II and Phase III trials of novel oncology agents such as gene therapy. Dr. Sorensen is also active in pursuing the development of novel neuroimaging, with active work in optical imaging, magnetoencephalography, and very high-field human MRI (3T and above).


Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty below have reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Peter Caravan, PhD, has no conflicts to report.
A. Gregory Sorensen, MD, has reported receiving salary from ACRIN, royalties from General Electric and Olea Medical, and has contracted research with NIH/NCI and Siemens.

The planners and managers below reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Jan Hixon, RN, BSN, MA
Trace Hutchison, PharmD
Julia Kimball, RN, BSN
Samantha Mattiucci, PharmD
Linda McLean, MS
Victoria Phoenix, BS
Jan Schultz, RN, MSN, CCMEP
Lisa Schleelein, MEd
Patricia Staples, MSN, NP-C, CCRN
Daniel R. Thedens, PhD

 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. PIM, ICPME, and Bayer Healthcare Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ICPME, and Bayer Healthcare Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



Questions

For questions regarding this program, please contact ICPME:
Email:
information@icpmed.com
Phone: 607-257-5860 x10




JOINTLY SPONSORED BY

               
 



SUPPORTED BY AN EDUCATIONAL GRANT FROM





Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.